{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling, creating an inflammatory state that sensitizes tumors to checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit",
          "line_ref": "L39"
        }
      ],
      "caveat": "While the interferon response and its necessity are well-supported by experimental controls, the precise molecular pathways of innate sensing in different tumor types may vary and require further characterization"
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination significantly expands the MHC-I presented peptide repertoire, improving tumor visibility to T cells",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
          "line_ref": "L29"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
          "line_ref": "L28"
        }
      ],
      "caveat": "The expansion in antigen presentation was demonstrated across multiple models but was characterized as strongest in specific model systems rather than uniformly consistent"
    },
    {
      "claim_id": "C03",
      "claim": "Combining intratumoral mRNA vaccination with anti-PD-L1 therapy improves tumor control in preclinical models through complementary mechanisms",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x",
          "line_ref": "L32"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
          "line_ref": "L33"
        }
      ],
      "caveat": "Preclinical efficacy may not translate directly to all human tumors; mouse model effects require validation in clinical trials"
    },
    {
      "claim_id": "C04",
      "claim": "Patients who received SARS-CoV-2 mRNA vaccination showed improved survival outcomes when undergoing immune checkpoint inhibitor treatment compared to unvaccinated patients",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01",
          "line_ref": "L30"
        },
        {
          "quote": "The vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "This finding is based on retrospective observational data; the analysis is non-randomized and subject to confounding factors including variable vaccination timing and heterogeneous patient characteristics"
    },
    {
      "claim_id": "C05",
      "claim": "The proposed mechanistic chain from mRNA vaccination to improved ICI responsiveness is biologically coherent and well-supported by the cumulative evidence",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling. 2. Interferon-associated antigen processing and presentation pathways increase. 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells. 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade. 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort",
          "line_ref": "L42"
        }
      ],
      "caveat": "While the overall mechanistic chain is coherent, individual steps and their relative contributions across different tumor types require further systematic investigation"
    }
  ]
}